Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon.

Suppr

超能文献

作者信息

Miyazaki S, Miura K, Kasai Y, Abe K, Yoshinaga K

出版信息

Br Med J (Clin Res Ed). 1982 Jan 30;284(6312):310-11. doi: 10.1136/bmj.284.6312.310.

DOI:10.1136/bmj.284.6312.310

PMID:6174171

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1495917/

Abstract

摘要

相似文献

Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon.

Br Med J (Clin Res Ed). 1982 Jan 30;284(6312):310-11. doi: 10.1136/bmj.284.6312.310.

Treatment of Raynaud's phenomenon with captopril.

Drugs Exp Clin Res. 1987;13(1):37-42.

[Treatment of Raynaud's syndrome with captopril].

Dtsch Med Wochenschr. 1984 Jun 1;109(22):857-60. doi: 10.1055/s-2008-1069287.

The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon.

Br J Dermatol. 1987 Dec;117(6):751-8. doi: 10.1111/j.1365-2133.1987.tb07356.x.

[Raynaud's disease treated with captopril (Capoten). A randomized double-blind cross-over study].

Ugeskr Laeger. 1984 Sep 3;146(36):2695-7.

A plethysmographic study of the effect of tetranicotinoylfructose (Bradilan) on digital blood flow in primary and secondary Raynaud's phenomenon.

Angiology. 1974 May;25(5):312-6. doi: 10.1177/000331977402500503.

Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.

Br Med J (Clin Res Ed). 1982 Oct 16;285(6348):1069-71. doi: 10.1136/bmj.285.6348.1069.

Laser-Doppler flowmetry in the assessment of "mild" Raynaud's phenomenon and its treatment.

Panminerva Med. 1990 Oct-Dec;32(4):151-4.

Angiotensin converting enzyme inhibitors in Raynaud's phenomenon.

Drugs. 1994 Dec;48(6):864-7. doi: 10.2165/00003495-199448060-00003.

Role of digital artery adrenoceptors in Raynaud's disease.

Vasc Med. 1997;2(1):1-7. doi: 10.1177/1358863X9700200101.

引用本文的文献

Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors.

Pharm World Sci. 1993 Oct 15;15(5):219-24. doi: 10.1007/BF01880630.

Angiotensin converting enzyme inhibitors in Raynaud's phenomenon.

Drugs. 1994 Dec;48(6):864-7. doi: 10.2165/00003495-199448060-00003.

Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Med Toxicol. 1986 Mar-Apr;1(2):122-41. doi: 10.1007/BF03259832.

Pathogenesis and treatment of Raynaud's phenomenon.

Cardiovasc Drugs Ther. 1990 Jan;4 Suppl 1:45-51. doi: 10.1007/BF00053426.

Subjective and objective assessment of enalapril in primary Raynaud's phenomenon.

Br J Clin Pharmacol. 1991 Apr;31(4):477-80. doi: 10.1111/j.1365-2125.1991.tb05565.x.

Raynaud's phenomenon: its relevance to scleroderma.

Ann Rheum Dis. 1991 Nov;50 Suppl 4(Suppl 4):839-45. doi: 10.1136/ard.50.suppl_4.839.

本文引用的文献

Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril.

Hypertension. 1981 Jan-Feb;3(1):18-22. doi: 10.1161/01.hyp.3.1.18.

Evidence for participation of kinins in the antihypertensive effect of converting enzyme inhibition.

Klin Wochenschr. 1981 Jan 15;59(2):69-74. doi: 10.1007/BF01477285.

Inhibitory effects of -guanidino acid esters on trypsin, plasmin, plasma kallikrein and thrombin.

Biochim Biophys Acta. 1972 Apr 7;268(1):221-4. doi: 10.1016/0005-2744(72)90218-5.

Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade.

N Engl J Med. 1979 Jun 21;300(25):1417-9. doi: 10.1056/NEJM197906213002505.

Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Science. 1977 Apr 22;196(4288):441-4. doi: 10.1126/science.191908.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验